Galecto to Participate in Leerink Partners 2026 Global Healthcare Conference
Rhea-AI Summary
Galecto (NASDAQ: GLTO) will participate in a fireside chat at the Leerink Partners 2026 Global Healthcare Conference on March 9, 2026 at 10:40 a.m. ET.
According to the company, management will webcast the presentation live and make an archived replay available for 30 days under the Investor Calendar on the company website.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
Biotech peers show mixed moves: QLGN up 7.72%, TOVX up 2.56% but also flagged in momentum data as down 7.55%, SLXN ranges from -1.43% to up 3.19%, while ENTO and BDRX are down 5.68% and 3.57%. No clear sector-wide pattern tied to this conference item.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 12 | Offering closed | Negative | -3.0% | Closed underwritten offering at $19.00 with full over-allotment exercise. |
| Feb 10 | Offering priced | Negative | +1.3% | Priced $275M common stock offering at $19.00 per share. |
| Feb 10 | Offering proposed | Negative | +1.3% | Proposed offering of common and Series C preferred stock for R&D funding. |
| Jan 12 | Strategic update | Positive | +6.4% | Outlined 2026 milestones and pipeline plans, supported by $285M PIPE runway. |
| Jan 06 | Leadership hires | Positive | +2.7% | Announced new COO and CMO and reiterated DMR-001 development timeline. |
Capital-raising offerings have produced mixed reactions, while strategic and leadership news skewed positive with supportive price moves.
Recent news for Galecto shows intensive capital and strategic activity. In January 2026, leadership additions and a 2026 milestones update, backed by a $285M PIPE, saw shares rise 2.73% and 6.44%. In February 2026, a proposed, priced, and then closed equity offering around $19.00 per share generated a modestly positive 1.3% reaction on announcement but a -3.03% move after closing. Today’s conference participation fits the non-price-moving, routine “news” category.
Regulatory & Risk Context
Galecto has an active automatic shelf registration on Form S-3ASR filed on 2026-02-10, effective and already used in at least 2 prospectus supplements (424B5) on 2026-02-10 and 2026-02-11, allowing issuance of common stock, preferred stock, debt securities, warrants and units over time.
Market Pulse Summary
This announcement highlights Galecto’s participation in a Leerink Partners healthcare conference on March 9, 2026, with a webcast and 30-day replay. Contextually, the company recently executed substantial equity offerings under an effective S-3ASR and outlined a cash-backed pipeline strategy. Investors monitoring this event may focus on management commentary around capital deployment, development timelines, and how the recently strengthened balance sheet supports advancing hematologic programs.
AI-generated analysis. Not financial advice.
BOSTON, March 02, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biotechnology company working to redefine care for people with hematologic disorders, today announced that company management will participate in a fireside chat at the Leerink Partners 2026 Global Healthcare Conference on Monday, March 9, 2026 at 10:40 a.m. ET.
A live webcast of the Company’s presentation will be available under the “News & Events” tab in the Investor Calendar section of the Company’s website at https://ir.galecto.com/news-and-events/events. An archived replay will be accessible for 30 days following the event.
About Galecto, Inc.
Galecto, Inc. is a clinical-stage biotechnology company advancing a pipeline of antibody therapeutics to transform treatment of a broad spectrum of hematological cancers. Galecto’s pipeline includes a highly differentiated mutant calreticulin (mut-CALR)-driven myeloproliferative neoplasm portfolio targeting essential thrombocythemia and myelofibrosis. Galecto’s pipeline also includes GB3226, a first-in-class preclinical dual inhibitor of ENL-YEATS and FLT3 for the treatment of multiple genetic subsets of acute myeloid leukemia.
Media Contact:
Lia Dangelico
Deerfield Group
lia.dangelico@deerfieldgroup.com
Investor Contact:
Brian Ritchie
LifeSci Advisors
britchie@lifesciadvisors.com
FAQ
When will Galecto (GLTO) present at the Leerink Partners 2026 Global Healthcare Conference?
How can investors watch Galecto's (GLTO) Leerink 2026 presentation live or later?
Where will the archived replay of Galecto's (GLTO) conference presentation be available and for how long?
What type of session will Galecto (GLTO) management take part in at the Leerink 2026 conference?
Will Galecto (GLTO) provide slides or additional materials for the Leerink Partners 2026 presentation?
